Paul Langan will join ORNL in the spring as associate laboratory director for the Biological and Environmental Systems Science Directorate.
Researchers at ORNL have developed a new method for producing a key component of lithium-ion batteries. The result is a more affordable battery from a faster, less wasteful process that uses less toxic material.
Although blockchain is best known for securing digital currency payments, researchers at the Department of Energy’s Oak Ridge National Laboratory are using it to track a different kind of exchange: It’s the first time blockchain has ever been used to validate communication among devices on the electric grid.
Over the past seven years, researchers in ORNL’s Geospatial Science and Human Security Division have mapped and characterized all structures within the United States and its territories to aid FEMA in its response to disasters. This dataset provides a consistent, nationwide accounting of the buildings where people reside and work.
Researchers at ORNL and the University of Tennessee, Knoxville, discovered a key material needed for fast-charging lithium-ion batteries. The commercially relevant approach opens a potential pathway to improve charging speeds for electric vehicles.
Scientists at ORNL used neutron scattering to determine whether a specific material’s atomic structure could host a novel state of matter called a spiral spin liquid.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
A force within the supercomputing community, Jack Dongarra developed software packages that became standard in the industry, allowing high-performance computers to become increasingly more powerful in recent decades.
Six ORNL scientists have been elected as fellows to the American Association for the Advancement of Science, or AAAS.
Experiments led by researchers at ORNL have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.